{
  "glycan_biomarkers": [
    {
      "assessed_biomarker_entity": {
        "glycan_entity": "\u03b12,6 sialylated N-glycans",
        "glycan_entity_change": "increased level",
        "glycoprotein_entity_name": "",
        "glycoprotein_gene_name": "",
        "glycoprotein_mapped": "",
        "glycoenzyme_entity_name": "ST6GAL1",
        "glycoenzyme_gene_name": "",
        "glycoenzyme_mapped": "Sialyltransferases|ST6GAL1 protein, human|beta-D-Galactoside alpha 2-6-Sialyltransferase"
      },
      "associated_disease": {
        "disease_name": "prostate cancer",
        "disease_mapped": "Prostatic Neoplasms",
        "medical_intervention": "sialyltransferase inhibitor P-3F<sub>AX</sub> -Neu5Ac"
      },
      "biomarker_role": [
        "diagnostic",
        "prognostic",
        "response"
      ],
      "sample": {
        "organism": "Humans",
        "specimen_type": "prostate cancer tissue|plasma",
        "specimen_mapped": "Prostatic Neoplasms|"
      },
      "evidence": {
        "pmid": "37550801",
        "sentence_in_abstract": "A common change in tumour cell glycosylation is an increase in \u03b12,6 sialylation of N-glycans, a modification driven by the sialyltransferase ST6GAL1."
      }
    }
  ]
}